William Audeh, MD
Chief Medical Officer, Agendia
Medical School
University of Iowa
Residency
Stanford University Medical Center
Fellowship(s)
Medical Oncology, Stanford University Medical Center
Area of Expertise
- Breast Cancer
- Precision Oncology
- Genetic Testing
- PARP Inhibitors
Years of Experience
Over 30 years
Certifications & Licensure
- American Board of Internal Medicine
- CA State Medical License
Biography
Dr. William Audeh is a compassionate medical oncologist with over 30 years of experience dedicated to improving the lives of breast cancer patients. He combines cutting-edge research with personalized patient care, focusing on precision oncology and genetic testing. Dr. Audeh’s expertise spans from leading clinical trials to developing innovative genomic tests for more accurate breast cancer diagnosis and treatment.
As the Chief Medical Officer at Agendia, Dr. Audeh leads the development of genomic subtyping tests that provide more precise information about specific types of breast cancer. His work has opened new doors in targeted therapies, particularly with PARP inhibitors for certain types of breast and ovarian cancers.
Dr. Audeh’s commitment extends beyond medical treatment. He is passionate about patient education and empowerment, frequently speaking at conferences and authoring numerous articles to help patients better understand their diagnosis and treatment options.
Awards, Honors & Recognitions
- William R. Wilson Award for Excellence in Internal Medicine, University of Iowa, 1982
- American Cancer Society Clinical Fellowship in Oncology, Stanford University, 1986-1987
- America’s Top Doctors, 2014
- Top Doctors: LA Area, 2013
- America’s Top Doctors for Cancer, 2013
- Top Doctors: Southern California, 2012
Publications
A breast cancer gene signature for indolent disease.
Leonie J. M. J. Delahaye, CA Drukker, Christa Dreezen, Anke T. Witteveen, Bob Chan, Mireille Snel, Ines J. Beumer, René Bernards, M. William Audeh, Laura J. van’t Veer, Annuska M. GlasOlaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Ursula A. Matulonis, Richard T. Penson, Susan M. Domchek, Bella Kaufman, Ronnie Shapira-Frommer, M. W. Audeh, Stan B. Kaye, L. R. Molife, Karen A. Gelmon, Jane Robertson, Helen Mann, Tony W. Ho, Robert L. ColemanEfficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M. Stemmer, Ayala Hubert, Ora Rosengarten, Niklas Loman, Jane Robertson, Helen Mann, Bella Kaufman
featured Articles
your Tumor
Understand the genomics of your tumor and what it means for breast cancer treatment.
The Fundamentals of Genomic Testing in Breast Cancer
Discover the fundamentals of genomic testing in breast cancer.
The DEBRA Trial and MammaPrint’s Role
The DEBRA Trial explores reducing radiation after surgery.
Featured Interview
Breakthroughs in Breast Cancer Treatment Testing
Testimonial
Latest News & Resources
News
Patient Resources
MEET OUR EXPERT MEDICAL TEAM
Explore the expertise of our medical advisors, who are dedicated to advancing breast cancer awareness, treatment, and support. Connect with our team and discover how their guidance contributes to the resources and insights available within our breast cancer support groups.
